Korelasi Ekspresi MicroRNA-155 dengan Grade Histopatologi pada Jaringan Kanker Payudara Tipe Duktal

  

DAFTAR PUSTAKA

American Cancer Society. 2013. Breast Cancer. 24th Nov 2013.

  American Cancer Society. 2013. Tumor Marker.

  

  Anderson E. Progesterone receptors

• – animal models and cell signaling in breast cancer: The role of oestrogen and progesterone receptors in human mammary development and tumorigenesis. Breast Cancer Res, 4; 197-201.

  Armstrong K., Eisen A., and Weber B. 2000. Assessing the Risk of Breast Cancer.

  N Engl J Med 342(8); 564-571.

  Australian Government. 2013. Breast Cancer Statistics. Cancer Australia.

   24th Nov 2013.

  Bartel D.P. 2004. MicroRNAs: Genomics, Biogenesis, Mechanism, and Function.

  Cell 116; 281 –297.

  Beger C., Pierce L.N., Kruger M., Marcusson E.G., Robbins J.M., Welcsh P., Welch P.J., Welte K., King M.C., Barber J.R., and Wong-Staal F. 2001.

  Identification of Id4 as a Regulator of BRCA1 Expression by Using a Ribozyme-library-based Inverse Genomics Approach. PNAS 98(1); 130-135.

  

101 Blenkiron C., Goldstein L.D., Thorne N.P., Spiteri I., Chin S.F., Dunning M.J., Barbosa-Morais N.L., Teschendorff A.E., Green A.R., Ellis I.O., Tavare S., Caldas C., and Miska E.A. 2007. MicroRNA Expression Profiling of Human Breast Cancer Identifies New Markers of Tumor Subtype. Genome Biology 8(10); R214.1-16.

  Bruning U., Cerone L., Neufeld Z., Fitzpatrick S.F., Cheong A, Scholz C.C., Simpson D.A. , Leonard M.O., Tambuwala M.M., Cummins E.P., and Taylor1 C.T. 2011. MicroRNA-155 Promotes Resolution of Hypoxia- Inducible Factor 1-Activity during Prolonged Hypoxia. Mol Cell Biol 31(19); p. 4087 –4096. Calin GA and Croce CM. 2006. MicroRNA Signatures in Human Cancers. Nature Rev. Cancer 6; 857-866.

  Chen L.J., Lim S.H., Yeh Y.T., Lien S.C., and Chiu J.J. 2012. Roles of microRNAs in Atherosclerosis and Restenosis. Journal of Biomedical

  Science 19(79); 1-13.

  Chen X., Ba Y., Ma L., Cai X., Yin Y., Wang K., Guo J., Zhang Y., Chen J., Guo X., Li Q., Li X., Wang W., Zhang Y., Wang J., Jiang X., Xiang Y., Xu C., Zheng P., Zhang J., Li R., Zhang H., Shang X., Gong T., Ning G., Wang J., Zen K., Zhang J., and Zhang C. 2008. Characterization of microRNAs in Serum: a Novel Class of Biomarkers for Diagnosis of Cancer and Other Diseases. Cell Research 18; 997-1006.

  Clurman B.E. and Hayward W.S. 1989. Multiple Proto-oncogene Activations in Avian Leukosis Virus-induced Lymphomas: Evidence for Stage-specific Events. Mol. Cell. Biol 9(6); 2657-2664.

  Connor E.B. and Stuenkel C.A. 2001. Hormone Replacement Therapy (HRT)- Risk and Benefits. Int J of Epidemiology 30; 423-426.

  Cortez M.A., Bueso-Ramos C., Ferdin J., Lopez-Berestein G., Sood A.K., and Calin G.A. 2011. MicroRNAs in Body Fluids

  —the Mix of Hormones and Biomarkers. Nat Rev Clin Oncol 8(8); 467 –477. Cronin P.A., Jiang H Wang J.H., and H Paul Redmond H.P. 2010. Hypoxia increases the metastatic ability of breast cancer cells via upregulation of

  CXCR4. BMC Cancer 10(225); 1-8.

Dağlar G., Yuksek Y.N., Gozalan A.U., Tutuncu T., Gungor Y., and Kama N.A

  2010. The Prognostic Value of Histopatological Grade in the Outcome of Patients with Invasive Breast Cancer. Turk J Med Sci 40(1); 7-15.

  Dahlan M.S. 2010. Besar Sampel dan Cara Pengambilan Sampel dalam

Penelitian Kedokteran dan Kesehatan . Edisi 3. Salemba Medika. Jakarta.

de Jong M.M., Nolte I.M., te Meerman G.J., van der Graaf W.T.A., Oosterwijk

  J.C., Kleibeuker J.H., Schaapveld M., and de Vries E.G.E. 2002. Genes Other than BRCA1 and BRCA2 Involved in Breast Cancer Susceptibility. J

  39; 225

  Med Genet –242.

  DEPKES RI. 2009. Pencegahan Kanker Leher Rahim dan Kanker Payudara.

  

  10 Apr 2014. th

  Duffy M.J. and McGing P. 2010. Guidelines for the use of Tumour Markers. 4 edition. Association of Clinical Biochemists in Ireland.

  Ergul E. and Sazci A. 2001. Molecular Genetics of Breast Cancer. Turk J Med Sci 31; 1-14.

  Esteller M. 2011. Non-coding RNAs in human disease. Nature 12; 861-874. Friedman R.C., Farh K.K.H., Burge C.B., Bartel D.P. 2009. Most Mammalian

• – mRNAs are Conserved Targets of microRNAs. Genome Research 19; 92 105.

  Gasco M., Shami S. and Crook T. 2002. The p53 Pathway in Breast Cancer.

  Breast Cancer Res 4; 70-76.

  Grazio S.F. and Bracko M. 2002. Long term Prognostic Value of Nottingham Histopatological Grade and its Components in Early (pT1N0M0) Breast Carcinoma. J Clin Pathol 55; 88 –92. Gregory R.I., Chendrimada T.P., Cooch N., Shiekhattar R. 2005. Human RISC

  Couples microRNA Biogenesis and Posttranscriptional Gene Silencing. Cell 123; 631 –640. Hall J.M., Lee M.K., Newman B., Morrow J.E., Anderson L.A., Huey B., and

  King M.C. 1990. Linkage of Early-onset Familial Breast Cancer to Chromosome 17q21. Science 250; 1684-1689.

  Han J., Lee Y., Yeom K.H. 2006. Molecular Basis for the Recognition of Primary microRNAs by the Drosha-DGCR8 Complex. Cell 125; 887

• –901. Harris L., Fritsche H., Mennel R., Norton L., Ravdin P., Taube S., Somerfield

  M.R., Hayes D.F., and Bast Jr R.C. 2007. American Society of Clinical

  Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer. J Clin Oncol 25; 5287-5312.

  Hauptman N. and Glavac D. 2013. MicroRNAs and Long Non-coding RNAs: Prospects in Diagnostics and Therapy of Cancer. Radiol Oncol 47(4); 311- 318.

  Hedenfalk I.A., Ringner M., Trent J.M., and Borg A. 2002. Gene Expression in Inherited Breast Cancer. Advances in Cancer Research 84; 1-34.

  He L., Thomson J.M., Hemann M.T., Hernando-Monge E., Mu D., Goodson S., Powers S., Cordon-Cardo C., Lowe S.W., Hannon G.J., and Hammond S.M.

  2005. A microRNA Polycistron as a Potential Human Oncogen. Nature 435; 828-833.

  He L., Long L.R., Antani S., Thoma G.R. Computer assisted diagnosis in histopathology . Chapter 15. National Institutes of Health, USA.

  

18th Feb 2014.

  Henry N.L. and Hayes D.F. 2006. Uses and Abuses of Tumor Markers in the Diagnosis, Monitoring, and Treatment of Primary and Metastatic Breast Cancer. The Oncologist 11; 541-552.

  Hui A., How C., Ito E., and Liu F. 2011. Micro-RNAs as Diagnostic or Prognostic Markers in Human Epithelial Malignancies. BMC Cancer 11; 500.p1-9.

  Huntzinger E., Izaurralde E. 2011. Gene Silencing by microRNAs: Contributions of Translational Repression and mRNA Decay. Nature 12; 99-110.

  Iorio M.V., Ferracin M., Liu C.G., Veronese A., Spizzo R., Sabbioni S., Magri E., Pedriali M., Fabbri M., Campiglio M., Me´nard S., Palazzo J.P., Rosenberg

  A, Musiani P., Volinia S., Nenci I., Calin G.A., Querzoli P., Negrini M., and Croce C.M. 2005. MicroRNA Gene Expression Deregulation in Human Breast Cancer. Cancer Res 65 (16); 7065-7070.

  Kon W., 2010. The Role of MicroRNA-155 in Human Breast Cancer.

  Dissertation. the degree of Doctor of Philosophy Department of Pathology and Cell Biology College of Medicine University of South Florida.

  Kumar V., Cotran R.S., dan Robbins SL. 2007. Buku Ajar Patologi Robbins.

  Sistem genitalia perempuan dan payudara: Payudara. Edisi 7. EGC.

  Jakarta. Lagos-Quintana M., Rauhut R., Yalcin A., Meyer J., Lendeckel W., and Tuschl T.

  2002. Identification of Tissue-Specific MicroRNAs from Mouse. Current

  Biology 12; 735 –739.

  Lee I., Cook N.R., Rexrode K.M., and Buring J.E. 2001. Lifetime physical activity and risk of breast cancer. British Journal of Cancer 85(7); 962

• –965. Lee R.C., Feinbaum R.L., Ambros V. 1993. The C. elegans Heterochronic Gene Encodes Small RNAs with Antisense Complementarity to lin-14. Cell

  lin-4 75; 843-854. Lee Y.H., Bedford M.T., and Stallcup M.R. 2011. Regulated recruitment of tumor suppressor BRCA1 to the p21 gene by coactivator methylation. Genes Dev 25; 176-188. Loman N., Bladström A., Johannsson O., Borg A., and Olsson H. 2003. Cancer incidence in relatives of a population-based set of cases of early-onset breast cancer with a known BRCA1 and BRCA2 mutation status. Breast Cancer Res 5; R175-R186.

  Lu Z., Ye Y., Jiao D., Qiao J., Cui S., and Liu Z. 2012. miR-155 and miR-31 are differentially expressed in breast cancer patients and are correlated with the estrogen receptor and progesterone receptor status. Oncology Letters 4; 1027-1032.

  Mandal

  A. 2013. Breast Cancer Epidemiology.

  Mar-Aguilar F., Mendoza- Ram´ırez J.A., Malag´on-Santiago I., Espino-Silva

  P.K., Santuario-Facio S.K., Ruiz- Flores P., Rodr´ıguez-Padilla C., and

  Res´endez-P´erez D. 2013. Serum circulating microRNA profiling for identification of potential breast cancer biomarkers. Disease Markers 34; 163 –169. Martinez-Sanchez A., Murphy C.L. 2013. MicroRNA Target Identification- Experimental Approaches. Biology 2; 189-205.

  Mattiske S., Suetani R.J, Neilsen P.M., Callen D.F. 2012. Cancer Epidemiol Biomarkers Prevention: The Oncogenic Role of miR-155 in Breast Cancer.

  American Association for Cancer Research. cebp.aacrjournals.org. 4th Sept 2013.

  Massagué J. 2008. TGF β in Cancer. Cell 134; 215-230. McTiernan A., Rajan K.B., Tworoger S.S., Irwin M., Bernstein L., Baumgartner R., Gilliland F., Stanczyk F.Z., Yasui Y., and Ballard-Barbash R. 2003.

  Adiposity and Sex Hormones in Postmenopausal Breast Cancer Survivors. J Clin Oncol 21; 1961-1966.

  Mendes N.D., Freitas A.T., Sagot M.F. 2009. Current tools for the identification

• – of miRNA genes and their target. Nucleic Acids Research 37 (8); 2419 2433.

  Miki Y., Swensen J., Shattuck-Eidens D., Futreal P.A., Harshman K., Tavtigian S., Liu Q., Cochran C., Bennett L.M., Ding W., Bell R., Rosenthal J., Hussey C., Tran T., McClure M., Frye C., Hattier T., Phelps R., Haugen- Strano A., Katcher H., Yakumo K., Gholami Z., Shaffer D., Stone S., Bayer S., Wray C., Bogden R., Dayananth P., Ward J., Tonin P., Narod S., Bristow P.K., Norris F.H., Helvering L., Morrison P., Rosteck P., Lai M., Barrett J.C., Lewis C., Neuhausen S., Cannon-Albright L., Goldgar D., Wiseman R., Kamb A., and Skolnick M.H. 1994. A Strong Candidate for the Breast and Ovarian Cancer Susceptibility Gene BRCA1. Science 266; 66-71.

  Mukherjee D. and Zhao J. 2013. The Role of chemokine receptor CXCR4 in breast cancer metastasis. Am J Cancer Res 3(1); 46-57.

  Oakley K.L. and Going J.J. 1995. Specimen Slice Radiography of Cancer in Breast Conserving Excisions. JClin Pathol 48; 1028-1030.

  Oemiati R., Rahajeng E., Kristanto A.Y. 2011. Prevalensi Tumor dan beberapa faktor yang Mempengaruhinya di Indonesia. Bul. Penelit. Kesehat 39(4); 190 – 204. Ostad S.N. and Parsa M. 2011. Breast Cancer from Molecular Point of View:

  Pathogenesis and Biomarkers. Chapter 6. Faculty of Pharmacy, Tehran University of Medical Sciences. Tehran.

  th

  10 Apr 2014. Ozsolak F., Poling L.L., Wang Z., Liu H., Liu X.S., Roeder R.G., Zhang X., Song

  J.S., Fisher D.E. 2008. Chromatin structure analyses identify miRNA promoters. Genes Dev 22; 3172-3183.

  Pöschl G. and Seitz H.K. 2004. Alcohol and Cancer. Alcohol & Alcoholism 39(3); pp.155

• –165. Rakha E.A., Reis-Filho J.S., Baehner F., Dabbs D.J., Decker T., Eusebi V., Fox

  S.B., Ichihara S., Jacquemier J., Lakhani S.R., Palacios J., Richardson A.L., Schnitt S.J., Schmitt F.C., Tan P., Tse G.M., Badve S., and Ellis I.O. 2010.

  Breast cancer prognostic classifi cation in the molecular era: the role of histopatological grade. Breast Cancer Research 12; 207.p1-12.

  Reinhart, B.J., Slack, F.J., Basson, M., Pasquinelli, A.E., Bettinger, J.C., Rougvie, A.E., Horvitz, H.R., and Ruvkun, G. 2000. The 21- nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature 403; 901 –906.

  Rodriguez A., Griffiths-Jones S., Ashurst J.L., Bradley A. 2004. Identification of mammalian microRNA host genes and transcription units. Genome Res 14; 1902 –1910. Saini H.K., Griffiths-Jones S., Enright A.J. 2007. Genomic analysis of human microRNA transcripts. Proc Natl Acad Sci USA 104; 17719

• –17724. Sen C.K., Gordillo G.M., Khanna S., Roy S. 2009. Micromanaging Vascular Biology: Tiny MicroRNAs Play Big Band. J Vasc Res 46; 527 –540.

  SHEN G, LI X, JIA Y,PIAZZA G.A., and XI Y. 2013. Hypoxia-regulated microRNAs in human cancer. Acta Pharmacologica Sinica 34; 336

• –341. Sjamsuhidajat R. dan de Jong W. 2004. Buku Ajar Ilmu Bedah. Tindakan bedah organ dan sistem organ: Payudara. Edisi 2. EGC. Jakarta.

  Stefansson O.A. and Esteller M. 2012. BRCA1 as a tumor suppressor linked to the regulation of epigenetic states: keeping oncomiRs under control. Breast

  Cancer Research 14; 304.

  Szafranska A.E., Davison T.S., Shingara J., Doleshal M., Riggenbach J.A., Morrison C.D., Jewell S., and Labourier E. 2008. Accurate Molecular Characterization of Formalin-Fixed, Paraffin-Embedded Tissues by microRNA Expression Profiling. JMD 10(5); 415-423.

  Taghian AG, Smith BL, Erban JK. 2010. Breast Cancer: A Multidisciplinary . Demos Medical. New York.

  Approach to Diagnosis and Management

  Tavassoli F.A and Devilee P. 2003. Pathology and Genetics: Tumours of the Breast and Female Genital Organs . WHO Classification of Tumours;5.

  IARC Press. Lyon. Terry P.D. and Rohan T.E. 2002. Cigarette Smoking and the Risk of Breast Cancer in Women: A Review of the Literature. Cancer Epidemiol Biomarkers Prev 11;953-971.

  Tryggvadottir L., Olafsdottir E.J., Gudlaugsdottir S., Thorlacius S., Jon G., Jonasson J.G., Tulinius H., and Eyfjord J.E. 2003. BRCA2 mutation carriers, reproductive factors and breast cancer Risk. Breast Cancer Res 5; R121- R128. Valencia-Sanchez M.A.V., Liu J., Hannon G.J., Parker R. 2006. Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev 20;

  515-524. Volinia S., Calin G.A., Liu C., Ambs S., Cimmino A., Petrocca F., Visone R.,

  Iorio M., Roldo C., Ferracin M., Prueitt R.L., Yanaihara N., Lanza G., Scarpa A., Vecchione A., Negrini M., Harris C.C., and Croce C.M. 2006. A microRNA expression signature of human solid tumors defines cancer gene targets. PNAS 103(7); 2257-2261. Wang F., Zhiguo Zheng Z., Guo J., and Ding X. 2010. Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor. Gynecol Oncol doi: 10.1016 /j.ygyno. 2010.07.021; 1-8. Weir H.K., Thun M.J., Hankey B.F., Ries L.A.G., Howe H.L., Wingo P.A., Jemal

  A., Ward E., Anderson R.N., Edwards B.K. 2003. Annual Report to the Nation on the Status of Cancer, 1975

• –2000, Featuring the Uses of

Surveillance Data for Cancer Prevention and Control. J Natl Cancer Inst 95(17); 1276-1299.

  WHO. 2013. Breast cancer: prevention and control.

  

http://www.who.int/cancer/detection/breastcancer/en/. 24th Nov 2013.

  Wrensch M., Chew T., Farren G., Barlow J., Belli F., Clarke C., Erdmann C.A., Lee M., Moghadassi M., Peskin-Mentzer R., Quesenberry Jr C.P., Souders- Mason V., Spence L., Suzuki M. and Gould M. 2003. Risk factors for breast cancer in a population with high incidence rates. Breast Cancer Res 5; R88- R102. Xia W., Cao G.J., Shao N.S. 2009. Progress in miRNA target prediction and identification. Sci China Ser C-Life Sci 52(12); 1123-1130.

  Zhao S.Y., Wu Q., Gao F., Zhang C.B., and Yang X.W. 2012. Serum microRNA- 155 as a potential biomarker for breast cancer screening. Chin Sci Bull 57; 3466-3468. Zheng W., Zou H., Tan Y., Cai W. 2011. Identification of MicroRNA Target

  Genes in Vivo. Mol Biotechnol 47; 200 –204. Zhu W., Qin W., Atasoy, Sauter E.R. 2009. Circulating microRNAs in breast cancer and healthy subjects. BMC Research Notes 2; 89.p1-5.